These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26140393)

  • 1. Improvements in body composition, anthropometric measurements and lipid profile following discontinuation of clozapine.
    Wysokiński A; Sobów T
    Nord J Psychiatry; 2016; 70(2):156-60. PubMed ID: 26140393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood serum levels of CART peptide in patients with schizophrenia on clozapine monotherapy.
    Wysokiński A; Kłoszewska I
    Psychiatry Res; 2014 Dec; 220(1-2):170-4. PubMed ID: 25219614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia.
    Bai YM; Chen JY; Yang WS; Chi YC; Liou YJ; Lin CC; Wang YC; Lin CY; Su TP; Chou P
    J Clin Psychiatry; 2007 Dec; 68(12):1834-9. PubMed ID: 18162013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood levels of glucose and insulin and insulin resistance in patients with schizophrenia on clozapine monotherapy.
    Wysokiński A
    Diabetes Metab Syndr; 2014; 8(4):236-41. PubMed ID: 25311817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.
    Melkersson K; Berinder K; Hulting AL
    Neuro Endocrinol Lett; 2011; 32(4):428-36. PubMed ID: 21876517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy?
    Softic R; Sutovic A; Avdibegovic E; Osmanović E; Bećirović E; Hajdukov MM
    Psychiatr Danub; 2015 Dec; 27(4):378-84. PubMed ID: 26609650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
    Sacchetti E; Galluzzo A; Valsecchi P; Romeo F; Gorini B; Warrington L;
    Schizophr Res; 2009 May; 110(1-3):80-9. PubMed ID: 19269791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increases in triglyceride levels are associated with clinical response to clozapine treatment.
    Lally J; Gallagher A; Bainbridge E; Avalos G; Ahmed M; McDonald C
    J Psychopharmacol; 2013 Apr; 27(4):401-3. PubMed ID: 23325369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uric acid levels in patients with schizophrenia on clozapine monotherapy.
    Wysokiński A; Kłoszewska I
    Nord J Psychiatry; 2015 Aug; 69(6):453-8. PubMed ID: 25801748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic ketoacidosis and severe hypertriglyceridaemia as a consequence of an atypical antipsychotic agent.
    Hepburn K; Brzozowska MM
    BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27507689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
    Henderson DC; Cagliero E; Gray C; Nasrallah RA; Hayden DL; Schoenfeld DA; Goff DC
    Am J Psychiatry; 2000 Jun; 157(6):975-81. PubMed ID: 10831479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
    Wu RR; Zhao JP; Zhai JG; Guo XF; Guo WB
    J Clin Psychopharmacol; 2007 Aug; 27(4):374-9. PubMed ID: 17632222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of AgRP protein in patients with schizophrenia on clozapine monotherapy.
    Wysokiński A; Kaźmierski J; Kłoszewska I
    Metab Brain Dis; 2015 Apr; 30(2):529-35. PubMed ID: 25034457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
    Correll CU; Frederickson AM; Kane JM; Manu P
    Schizophr Res; 2007 Jan; 89(1-3):91-100. PubMed ID: 17070017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
    Ascher-Svanum H; Zhu B; Faries D; Landbloom R; Swartz M; Swanson J
    BMC Psychiatry; 2006 Feb; 6():8. PubMed ID: 16504026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
    Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
    Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid dose-dependent effect of clozapine on a schizophrenic patient's lipid profile.
    Chiang HL; Liu CC; Hwang TJ
    J Psychopharmacol; 2009 Jun; 23(4):465-7. PubMed ID: 18562410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome.
    Zimbron J; Khandaker GM; Toschi C; Jones PB; Fernandez-Egea E
    Eur Neuropsychopharmacol; 2016 Sep; 26(9):1353-1365. PubMed ID: 27496573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program.
    Wu MK; Wang CK; Bai YM; Huang CY; Lee SD
    Psychiatr Serv; 2007 Apr; 58(4):544-50. PubMed ID: 17412858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.